The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

研究成果: 雜誌貢獻回顧型文獻

摘要

Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.
原文英語
頁(從 - 到)123-126
頁數4
期刊台灣癌症醫學雜誌
4
發行號4
DOIs
出版狀態已發佈 - 2017

指紋

Immunity
Fibroblasts
Drug Therapy
Neoplasms
Carcinoma
Maximum Tolerated Dose
Neoplastic Stem Cells
Poisons
Pancreatic Neoplasms
Breast Neoplasms
Therapeutics

Keywords

  • Carcinoma-associated fibroblasts
  • Metronomic chemotherapy
  • Cancer stemness
  • Myeloid-derived suppressor cells

引用此文

@article{235e18011cc44812b3245b23138d4856,
title = "The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity",
abstract = "Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.",
keywords = "Carcinoma-associated fibroblasts, Metronomic chemotherapy, Cancer stemness, Myeloid-derived suppressor cells",
author = "Wen-Ying Liao and Tze-Sian Chan and Tsai, {Kelvin K.}",
year = "2017",
doi = "10.1016/j.jcrpr.2017.08.001",
language = "English",
volume = "4",
pages = "123--126",
journal = "Journal of Cancer Research and Practice",
issn = "2311-3006",
publisher = "中華民國癌症醫學會",
number = "4",

}

TY - JOUR

T1 - The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity

AU - Liao, Wen-Ying

AU - Chan, Tze-Sian

AU - Tsai, Kelvin K.

PY - 2017

Y1 - 2017

N2 - Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.

AB - Metronomic chemotherapy involves the administration of cytotoxic chemotherapy at reduced doses administered at regular and frequent intervals. Low-dose metronomic (LDM) chemotherapy represents an alternative to standard maximum tolerated dose (MTD) chemotherapy as it is less toxic and offers additional beneficial biological effects; such effects include inhibition of tumor neovascularization and reduced recruitment of immune-suppressive cells. In desmoplastic cancers such as breast and pancreatic cancers, carcinoma-associated fibroblasts (CAFs) in the tumor stroma constitute an important cellular target of systemic chemotherapy, and the treatment-modulated CAFs may deleteriously influence treatment efficacy. Herein, we reviewed the novel roles of CAFs in metronomic chemotherapy in desmoplastic cancers. We discuss the differential effects of MTD- and LDM-chemotherapy on the heterotypic interactions among CAFs and cells in the other cancer compartments, emphasizing the roles of cancer stem cells and myeloid-derived suppressor cells. The novel mechanistic roles of CAFs in cancer therapy provide an additional rationale for the clinical development of LDM chemotherapy.

KW - Carcinoma-associated fibroblasts

KW - Metronomic chemotherapy

KW - Cancer stemness

KW - Myeloid-derived suppressor cells

U2 - 10.1016/j.jcrpr.2017.08.001

DO - 10.1016/j.jcrpr.2017.08.001

M3 - Review article

VL - 4

SP - 123

EP - 126

JO - Journal of Cancer Research and Practice

JF - Journal of Cancer Research and Practice

SN - 2311-3006

IS - 4

ER -